| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2009;53:532.)
© 2009 American Heart Association, Inc.
Original Articles |
From the Department of Medicine (D.X.Z., S.A.M., A.H.B., D.D.G.), Cardiovascular Center (D.X.Z., S.A.M., A.H.B., D.C.W., D.D.G.), and Departments of Anesthesiology (Z.-D.G., D.C.W.), and Pathology (R.L.), Medical College of Wisconsin, Milwaukee; Veterans Administration Medical Center (D.D.G.), Milwaukee, Wis; and the Department of Pharmacology (A.M., M.S.), Jichi Medical University, Tochigi, Japan.
Correspondence to David X. Zhang, Department of Medicine, Cardiovascular Center, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail xfzhang{at}mcw.edu
| Abstract |
|---|
|
|
|---|
-phorbol-12,13-didecanoate increased endothelial [Ca2+]i in situ, which was reversed by the TRPV4 blocker ruthenium red. In wild-type animals, acetylcholine dilated small mesenteric arteries that involved both NO and endothelium-derived hyperpolarizing factors. In TRPV4-deficient mice, the NO component of the relaxation was attenuated and the endothelium-derived hyperpolarizing factor component was largely eliminated. Compared with their wild-type littermates, TRPV4-deficient mice demonstrated a blunted endothelial Ca2+ response to acetylcholine in mesenteric arteries and reduced NO release in carotid arteries. Acetylcholine (5 mg/kg, IV) decreased blood pressure by 37.0±6.2 mm Hg in wild-type animals but only 16.6±2.7 mm Hg in knockout mice. We conclude that acetylcholine-induced endothelium-dependent vasodilation is reduced both in vitro and in vivo in TRPV4 knockout mice. These findings may provide novel insight into mechanisms of Ca2+ entry evoked by chemical agonists in endothelial cells.
Key Words: transient receptor potential endothelium endothelium-derived factors NO calcium
| Introduction |
|---|
|
|
|---|
The discovery of transient receptor potential (TRP) channels provides new insights into potential mechanisms of Ca2+ entry in endothelial cells. TRP channel–mediated Ca2+ entry has been implicated in diverse responses, including changes in vascular permeability, angiogenesis, vascular remodeling, and vasorelaxation.3,4 Of many subtypes of TRP channels expressed in endothelial cells, TRP vanilloid type 4 (TRPV4) channels have received increasing attention. These channels are widely expressed in vascular endothelial cells of several species and activated by both chemical and physical stimuli, including hypotonic cell swelling,5,6 moderate heating (>27°C),7,8 shear stress,9 and the synthetic phorbol-derivative 4
-phorbol-12,13-didecanoate (4
-PDD),10 as well as arachidonic acid and its metabolites.11,12 The TRPV4 channel has also been implicated in the release of endothelial-derived relaxing factors and regulation of vascular tone.13–16
Study of TRP channels in endothelial cells has been challenging because of the lack of specific channel blockers and coexpression of multiple TRP channels in the endothelium. Recently, 2 lines of TRPV4-deficient mice have been generated and found to exhibit phenotypic changes in several body systems, such as altered regulation of systemic tonicity, defects in the alveolar barrier, deficits in renal tubular K+ secretion, and blunted arterial shear response.15–20 Using this knockout mouse model, the present study examined the role of TRPV4 channels in agonist-induced endothelial Ca2+ signaling and endothelium-dependent vasodilation. Both in vitro and in vivo vascular responses were examined.
| Methods |
|---|
|
|
|---|
Animals
Fifty-two male TRPV4 knockout (TRPV4–/–)18 and 60 male wild-type (WT) C57BL/6J mice at 2 to 4 months of age were used in this study. All of the experiments were conducted in accordance with the Institutional Animals Care and Use Committee guidelines.
RNA Extraction and RT-PCR
Total RNA from vascular tissues was extracted with TRIzol, and cDNA was synthesized, followed by PCR amplification of TRPV4 and platelet/endothelial cell adhesion molecule 1 fragments using gene-specific primers.
Western Blot Analysis
Protein samples (20 µg) were subjected to 10% SDS-PAGE, and membranes were blotted with a polyclonal antibody against TRPV4 (1:1000 dilution; MBL International), followed by peroxidase-conjugated secondary antibodies. To ensure equal protein loading, the blots were reprobed with a polyclonal anti-endothelial NO synthase antibody (1:1000 dilution; BD Transduction Laboratories).
Immunohistochemistry
Frozen tissue sections were incubated with a polyclonal antibody against TRPV4 (1:100 dilution; Alomone Laboratories), followed by a goat antirabbit IgG conjugated with Alexafluor 568. Images were captured using a regular fluorescence microscope.
Measurement of Intracellular Ca2+
Endothelial intracellular Ca2+ ([Ca2+]i) was measured in situ in freshly isolated mesenteric arteries using Fura-2, as we described previously.21
Measurement of Endothelial NO
The fluorescent NO indicator 4-amino-5-methylamino-2',7'-difluorofluorescein or diaminofluorescein-FM (DAF-FM) diacetate was used to measure endothelial NO in situ in freshly isolated carotid arteries.21
Isometric Tension Recording
Small mesenteric arteries (first-order branch from superior mesenteric artery,
200 µm) were dissected and mounted in a wire myograph, as described previously.22
Measurement of Vascular Responses In Vivo
TRPV4–/– and WT mice were anesthetized with 12% urethane (1.2 g/kg body weight, IP) or ketamine/xylazine (50 mg/kg/10 mg/kg, IP). The right common carotid artery was cannulated for measurement of arterial blood pressure and the tail vein for drug administration. Heart rate was monitored by ECG at the V6 position. All of the drugs were given as a single IV bolus, including acetylcholine (15 µg/kg), 4
-PDD (1 µg/kg), phenylephrine (1 mg/kg), and sodium nitroprusside (5 mg/kg).
Data Analysis
Data are presented as means±SEMs. Significant differences between mean values were evaluated by Student t test or ANOVA followed by the Students-Newman-Keuls multiple comparison test. A value of P<0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
95 and
110 kDa in WT mice. The 95-kDa band is in good agreement with the calculated molecular weight of the unprocessed TRPV4 protein (98 kDa). The 110-kDa band presumably represents the glycosylated form of the TRPV4 protein.23 Immunohistochemical analysis revealed a strong staining for TRPV4 in the endothelium of WT aortic sections (Figure 1D). There was much less immunofluorescence in underlying smooth muscles. Hematoxylin and eosin staining confirmed an intact vascular structure of tissue sections from WT and TRPV4–/– mice.
|
We examined the TRPV4-mediated Ca2+ response in the endothelium in situ of isolated mesenteric arteries. As shown in Figure 2, infusion of 4
-PDD (1 µmol/L), a specific TRPV4 channel opener, elicited a rapid increase in [Ca2+]i in endothelial cells of WT mice (
[Ca2+]i: 105.8±13.2 nmol/L). This response was rapidly reversed by the addition of ruthenium red (10 µmol/L), a TRPV4 channel blocker (
[Ca2+]i: 30.4±3.3 nmol/L). Preincubation of arteries with ruthenium red also prevented endothelial Ca2+ response to 4
-PDD, whereas ruthenium red itself had no significant effect on basal [Ca2+]i in WT or TRPV4–/– mice (data not shown). 4
-PDD did not induce significant Ca2+ influx in mesenteric arteries of TRPV4–/– mice (
[Ca2+]i: 11.2±1.0 nmol/L). Removal of the endothelium at the end of experiments abolished the fluorescence, confirming that the measured fluorescence is specific to endothelial cells.
|
TRPV4 in Agonist-Induced Vasodilation In Vitro
In mouse mesenteric arteries, acetylcholine elicited concentration-dependent relaxations (maximal dilation: 93.3±2.2%; –logEC50: 7.7±0.1; Figure 3A). Pretreatment of arteries with a NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), markedly inhibited acetylcholine-induced relaxations (maximal dilation: 34.8±4.7%; –logEC50: 6.7±0.3). The addition of the cyclooxygenase inhibitor indomethacin had no further effect (maximal dilation: 40.8±4.7%; –logEC50: 6.3±0.5). The residual dilation in the presence of L-NAME and indomethacin was abolished by high K+ (maximal dilation: 5.3±9.3%). These results confirm the involvement of both NO and K+ channels (or EDHF) in acetylcholine-induced relaxations.
|
Compared with WT mice, acetylcholine-induced vasodilation was significantly reduced in TRPV4–/– mice (maximal dilation: 49.9±8.3% versus 88.1±3.5% for WT; –logEC50: 6.6±0.3 versus 7.2±0.1 for WT; Figure 3B). L-NAME largely eliminated acetylcholine-induced vasodilation in TRPV4–/– animals (maximal dilation of 9.0±2.3%). Endothelium-independent dilation to papaverine was similar in TRPV4–/– and WT mice (maximal dilation: 94.8±1.1% and 98.8±0.6%, respectively; Figure 3C). Furthermore, there was no difference in contractile responses to U46619 or high K+ between those animals (data not shown). 4
-PDD (1 µmol/L) also induced marked relaxations of intact but not denuded mesenteric arteries, with maximal relaxations of 87.9±5.0% and 1.0±2.5%, respectively (n=4 vessels from 4 mice).
Blood Pressure Response to Agonists
Resting arterial pressures and heart rates were similar in TRPV4–/– and WT mice, with mean values of 82.5±3.5 versus 92.3±8.3 mm Hg (P=0.2; n=14 and 10, respectively), and 497±28 versus 499±31 bpm (P value not significant), respectively. The systolic and diastolic blood pressures in TRPV4–/– and WT mice were 69.3±4.8 and 99.5±2.9 mm Hg and 75.1±5.6 and 112.6±11.9 mm Hg (P value not significant for both), respectively. Intravenous acetylcholine acutely reduced blood pressure in WT mice (mean change: 37.0±6.2 mm Hg 3 to 5 minutes after acetylcholine injection; Figure 4A). This response was significantly blunted in TRPV4–/– mice (mean reduction: 16.6±2.7 mm Hg). Acetylcholine produced a similar drop in heart rate in TRPV4–/– and WT mice (mean changes: 216±48 and 224±61 bpm, respectively; Figure 4B). When animals were matched for baseline blood pressure (>80 mm Hg), the acetylcholine-induced reduction in blood pressure was also significantly lower in TRPV4–/– versus WT animals, with mean decreases of 19.1±4.0 and 38.0±7.4, respectively. Baseline MAPs were found to be 91.0±3.3 and 102±5.3 mm Hg for matched TRPV4–/– and WT mice, respectively (P=0.1; n=8 for both).
|
4
-PDD transiently lowered blood pressure in WT but not in TRPV4–/– mice, with mean arterial blood pressure changes of 18.8±7.1 and –3.8±1.7 mm Hg, respectively (Figure 4C). Phenylephrine caused similar blood pressure increases in TRPV4–/– and WT mice (mean changes: 31.5±3.7 and 38.5±3.8 mm Hg, respectively). Nitroprusside similarly reduced blood pressure in TRPV4–/– and WT animals (mean changes: 55.5±7.2 and 61.7±5.5 mm Hg, respectively; n=6 to 8).
TRPV4 in Acetylcholine-Induced Ca2+ and NO Increase
Acetylcholine induced a rapid increase in endothelial [Ca2+]i of mesenteric arteries from WT mice, with [Ca2+]i changes of 47.8±4.4 and 31.2±4.4 nmol/L at peak and 1 minute after peak, respectively (Figure 5). Compared with WT controls, the Ca2+ response was more transient and of less magnitude in TRPV4–/– mice, with [Ca2+]i changes of 17.9±1.3 and 5.9±0.3 nmol/L at peak and 1 minute after peak, respectively. This is consistent with a role for TRPV4 in endothelial Ca2+ entry during the plateau phase of Ca2+ response.
|
We also measured NO production in vascular tissues of TRPV4–/– and WT mice using DAF fluorescence assay. The carotid arteries were used because acetylcholine-induced relaxations are mainly mediated by NO in this vascular bed (data not shown). As shown in Figure 6, acetylcholine induced a rapid increase in DAF fluorescence in the endothelial cell layer of WT carotid arteries. This increase was significantly reduced in the presence of L-NAME, confirming that increased DAF fluorescence is attributable to NO release. TRPV4–/– mice exhibited a markedly blunted response to acetylcholine. The basal level of DAF fluorescence was also lower in TRPV4–/– mice versus WT control mice.
|
| Discussion |
|---|
|
|
|---|
Consistent with the results of previous studies,24–26 we found that both NO and EDHF contribute to endothelium-dependent relaxation induced by acetylcholine in mouse mesenteric arteries. Compared with WT mice, the L-NAME–sensitive component of acetylcholine-induced relaxation was reduced in TRPV4–/– mice, whereas the K+-sensitive relaxation was virtually abolished, indicating that the TRPV4 channel is involved in both NO- and EDHF-dependent vasodilation. The involvement of TRPV4 channels in NO-mediated dilation was also supported by the observation that acetylcholine-induced NO production was significantly reduced in vascular endothelial cells of TRPV4–/– mice. These results are generally in agreement with previous reports that activation of TRPV4 channels induces NO- and EDHF-dependent vasodilation in rat carotid and gracilis arteries, as well as rat cerebral arteries.13,14
An agonist-induced increase in [Ca2+]i is critical in the synthesis of relaxing factors such as NO and EDHF in endothelial cells.1 However, the [Ca2+]i threshold is higher for EDHF-dependent dilation than for NO-dependent responses.27 Therefore, reduction in endothelial Ca2+ would have a greater effect on EDHF-mediated than NO-mediated relaxation. This may partially explain our findings that TRPV4–/– affected the K+-sensitive relaxation more than the NO-mediated relaxation in small mesenteric arteries, a resistance vascular bed where EDHF-mediated dilation is more prominent. TRPV4 activation and resulting Ca2+ influx may also selectively elicit the generation of EDHF and/or NO through specific signaling systems located in subcellular domains. TRPV4 channels have been shown to form a Ca2+ signaling complex with ryanodine receptors and large-conductance Ca2+-activated K+ channels in vascular smooth muscle cells.28 A recent study has also reported a close association of Ca2+ influx and EDHF-mediated relaxation in the caveolar microdomain of endothelial cells.26
In contrast to blood pressure changes, acetylcholine induced similar drops in the heart rate in TRPV4–/– animals compared with WT control animals, indicating that TRPV4 plays a minimal role in the control of heart rate in these animals. A recent study has also reported that TRPV4 agonists have no significant effect on rate or contractility in the isolated, buffer-perfused rat heart.29
Acetylcholine-induced Ca2+ increase (plateau phase) was reduced but not eliminated in TRPV4–/– mice, indicating that other Ca2+ entry pathways may coexist in vascular endothelial cells. Other TRP channels including TRPC (canonical) and TRPM (Melastatin) subfamilies have been found in endothelial cells.4 Several TRPC channels have been proposed as store-operated Ca2+ channels in response to agonist stimulation.4 A previous study indicates that agonist-induced endothelial Ca2+ current and vasodilation is reduced in the aorta from TRPC4–/– mice.30 In another recent study, Fleming et al31 reported that bradykinin induces translocation of TRPC6 to the cell membrane and TRP channel-mediated Ca2+ influx in human endothelial cells. Future studies are required to determine whether these TRP channels contribute to the remaining Ca2+ entry in endothelial cells of TRPV4–/– animals.
Immunohistochemical analysis of mouse aorta revealed that TRPV4 channels are mainly expressed in the endothelium. However, a TRPV4 channel has also been found in vascular smooth muscle cells of rat aortic, cerebral. and pulmonary arteries.14,28,32,33 We also found evidence for the TRPV4 protein in human and bovine coronary vascular smooth muscle but in much smaller amounts than in endothelial cells (unpublished observations). Therefore, expression of TRPV4 channels in vascular smooth muscle cells may depend on species and vascular beds. However, denuded mouse mesenteric arteries do not dilate to 4
-PDD; thus, we conclude that any TRPV4 channels in vascular smooth muscle do not contribute to the observations made in this study.
Baseline blood pressure in TRPV4–/– mice was not statistically higher than in their WT controls, as might be expected from reduced release of endothelial relaxing factors. In contrast, a trend toward lower blood pressure was observed in TRPV4–/– animals. These results are consistent with those of a previous study in unanesthetized animals.34 Although not further explored in the current study, the absence of baseline blood pressure change in TRPV4–/– mice could reflect compensatory pressure homeostatic mechanisms that minimize blood pressure changes observed in TRPV4–/– mice. Alternatively, compared with the mesenteric circulation examined in this study, TRPV4 expression and function might be different in other vascular beds. A conditional TRPV4 knockout specific to endothelial cells would help to address this possibility in future studies.
Perspectives
TRPV4 channels are expressed in endothelial cells of various species and vascular beds. Given the complex expression pattern of TRP channels and lack of specific channel blockers, TRPV4–/– mice provide a good model to study molecular and functional properties of endothelial TRPV4 channels in its native cellular environment. Our data suggest that TRPV4 channels, known to be involved in vascular mechanotransduction, are also involved in chemical agonist-induced increases in endothelial Ca2+ and endothelium-dependent vasodilation. However, the cellular mechanisms responsible for TRPV4 activation, ie, via receptor or store-operated mechanism, remain to be determined. Because activation of TRPV4 by channel agonists reduces blood pressure, the endothelial TRPV4 channel might serve as a novel pharmacological target for the treatment of hypertension.13 It will also be of interest to determine whether TRPV4-mediated endothelial responses are altered in other cardiovascular diseases, eg, atherosclerosis, where pharmacological manipulation of channel function might have beneficial therapeutic effects.
| Acknowledgments |
|---|
This work was supported by the American Heart Association (grant 0830042N to D.X.Z.) and National Heart, Lung, and Blood Institute (grants HL067968 and HL08070 to D.D.G.).
Disclosures
None.
Received December 6, 2008; first decision December 22, 2008; accepted January 6, 2009.
| References |
|---|
|
|
|---|
2. Clapham DE. Calcium signaling. Cell. 1995; 80: 259–268.[CrossRef][Medline] [Order article via Infotrieve]
3. Nilius B, Droogmans G, Wondergem R. Transient receptor potential channels in endothelium: solving the calcium entry puzzle? Endothelium. 2003; 10: 5–15.[CrossRef][Medline] [Order article via Infotrieve]
4. Yao X, Garland CJ. Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res. 2005; 97: 853–863.
5. Strotmann R, Harteneck C, Nunnenmacher K, Schultz G, Plant TD. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol. 2000; 2: 695–702.[CrossRef][Medline] [Order article via Infotrieve]
6. Liedtke W, Choe Y, Martí-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, Heller S. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 2000; 103: 525–535.[CrossRef][Medline] [Order article via Infotrieve]
7. Güler AD, Lee H, Iida T, Shimizu I, Tominaga M, Caterina M. Heat-evoked activation of the ion channel, TRPV4. J Neurosci. 2002; 22: 6408–6414.
8. Watanabe H, Vriens J, Suh SH, Benham CD, Droogmans G, Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells. J Biol Chem. 2002; 277: 47044–47051.
9. Gao X, Wu L, O'Neil RG. Temperature-modulated diversity of TRPV4 channel gating: activation by physical stresses and phorbol ester derivatives through protein kinase C-dependent and -independent pathways. J Biol Chem. 2003; 278: 27129–27137.
10. Watanabe H, Davis JB, Smart D, Jerman JC, Smith GD, Hayes P, Vriens J, Cairns W, Wissenbach U, Prenen J, Flockerzi V, Droogmans G, Benham CD, Nilius B. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002; 277: 13569–13577.
11. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003; 424: 434–438.[CrossRef][Medline] [Order article via Infotrieve]
12. Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, Nilius B. Modulation of the Ca2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res. 2005; 97: 908–915.
13. Köhler R, Heyken WT, Heinau P, Schubert R, Si H, Kacik M, Busch C, Grgic I, Maier T, Hoyer J. Evidence for a functional role of endothelial transient receptor potential V4 in shear stress-induced vasodilatation. Arterioscler Thromb Vasc Biol. 2006; 26: 1495–1502.
14. Marrelli SP, O'neil RG, Brown RC, Bryan RM Jr. PLA2 and TRPV4 channels regulate endothelial calcium in cerebral arteries. Am J Physiol Heart Circ Physiol. 2007; 292: H1390–H1397.
15. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grgic I, Harteneck C, Liedtke W, Hoyer J, Köhler R. Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS ONE. 2007; 2: e827.[CrossRef][Medline] [Order article via Infotrieve]
16. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, Fleming I. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res. 2008; 80: 445–452.
17. Liedtke W, Friedman JM. Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci U S A. 2003; 100: 13698–13703.
18. Suzuki M, Mizuno A, Kodaira K, Imai M. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003; 278: 22664–22668.
19. Alvarez DF, King JA, Weber D, Addison E, Liedtke W, Townsley MI. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res. 2006; 99: 988–995.
20. Taniguchi J, Tsuruoka S, Mizuno A, Sato J, Fujimura A, Suzuki M. TRPV4 as a flow sensor in flow-dependent K+ secretion from the cortical collecting duct. Am J Physiol Renal Physiol. 2007; 292: F667–F673.
21. Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TNF-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol. 2002; 283: H1785–H1794.
22. Zhang DX, Gauthier KM, Chawengsub Y, Campbell WB. ACh-induced relaxations of rabbit small mesenteric arteries: role of arachidonic acid metabolites and K+. Am J Physiol Heart Circ Physiol. 2007; 293: H152–H159.
23. Arniges M, Fernández-Fernández JM, Albrecht N, Schaefer M, Valverde MA. Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and trafficking. J Biol Chem. 2006; 281: 1580–1586.
24. Ding H, Kubes P, Triggle C. Potassium- and acetylcholine-induced vasorelaxation in mice lacking endothelial nitric oxide synthase. Br J Pharmacol. 2000; 129: 1194–1200.[CrossRef][Medline] [Order article via Infotrieve]
25. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000; 106: 1521–1530.[Medline] [Order article via Infotrieve]
26. Saliez J, Bouzin C, Rath G, Ghisdal P, Desjardins F, Rezzani R, Rodella LF, Vriens J, Nilius B, Feron O, Balligand JL, Dessy C. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation. 2008; 117: 1065–1074.
27. Marrelli SP. Mechanisms of endothelial P2Y(1)- and P2Y(2)-mediated vasodilatation involve differential [Ca2+]i responses. Am J Physiol Heart Circ Physiol. 2001; 281: H1759–H1766.
28. Earley S, Heppner TJ, Nelson MT, Brayden JE. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res. 2005; 97: 1270–1279.
29. Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulpizio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, Lashinger ES, Figueroa DJ, Marquis R, Xu X. Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: part 2. J Pharmacol Exp Ther. 2008; 326: 443–452.
30. Freichel M, Suh SH, Pfeifer A, Schweig U, Trost C, Weissgerber P, Biel M, Philipp S, Freise D, Droogmans G, Hofmann F, Flockerzi V, Nilius B. Lack of an endothelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in TRP4-/- mice. Nat Cell Biol. 2001; 3: 121–127.[CrossRef][Medline] [Order article via Infotrieve]
31. Fleming I, Rueben A, Popp R, Fisslthaler B, Schrodt S, Sander A, Haendeler J, Falck JR, Morisseau C, Hammock BD, Busse R. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol. 2007; 27: 2612–2618.
32. Tanaka R, Muraki K, Ohya S, Yamamura H, Hatano N, Itoh Y, Imaizumi Y. TRPV4-like non-selective cation currents in cultured aortic myocytes. J Pharmacol Sci. 2008; 108: 179–189.[CrossRef][Medline] [Order article via Infotrieve]
33. Yang XR, Lin MJ, McIntosh LS, Sham JS. Functional expression of transient receptor potential melastatin- and vanilloid-related channels in pulmonary arterial and aortic smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2006; 290: L1267–L1276.
34. Mizuno A, Matsumoto N, Imai M, Suzuki M. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003; 285: C96–C101.
This article has been cited by other articles:
![]() |
S. Earley, T. Pauyo, R. Drapp, M. J. Tavares, W. Liedtke, and J. E. Brayden TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1096 - H1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ellis, K. Goto, D. J. Chaston, T. D. Brackenbury, K. R. Meaney, J. R. Falck, R. J. H. Wojcikiewicz, and C. E. Hill Enalapril Treatment Alters the Contribution of Epoxyeicosatrienoic Acids but Not Gap Junctions to Endothelium-Derived Hyperpolarizing Factor Activity in Mesenteric Arteries of Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 413 - 422. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |